Global Herpes Labialis Drugs Market Size, Share and Trend Analysis Report, By Drug Type (Valacyclovir, Penciclovir, Famciclovir, and Docosanol), By Route of Administration (Oral, Topical, and Combination), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast (2022-2028)

The global herpes labialis drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Herpes labialis is a viral infection caused by the herpes simplex virus 1 (HSV-1) this is commonly related to wounds due to cold or herpes simplex virus 2 (HSV-2). Herpes labialis is usually occurred due to swelling of lips and the round facial areas near the mouth. The infection is occurred in childhood and to a certain extent is inactive in the nervous system. There are some serious health issues that can occur in newborn babies or people who have the weak immune system.  The growing prevalence of herpes labialis among children and adults across the globe is the factor that is driving the market growth. Herpes labialis is caused by herpes simplex virus type 1 (HSV-1). Therefore, the increase in the herpes simplex infections such as genital herpes is leading to an increasing growth of the market. However, the high cost of treatment and strict government rules and regulations related to drug approval is expected to lower the growth of the market. Also, side effects related use of drugs and people ignoring the treatment for herpes would be a restraint for the growth of the market.

Some major players in the market include GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in April 2021, Pfizer Inc. announced the acquisition of Amplyx Pharmaceuticals Inc, a US-based company to help them advance their anti-infective pipeline, and expand their product portfolio of antifungals and antiviral treatments.

Also, in 2020, Perrigo Company Plc announced the launch of its AB-rated Generic Zovirax cream. This product contains acyclovir and can be used to reduce further complications in all types of herpes. In October 2021, United BioPharma, Inc. collaborated with Shanghai Public Health Clinical Centre and Cheng Kung University’s Department of Microbiology and Immunology to investigate the efficacy of UB-621, a best-in-class long-acting medication for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2).

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug Type
  • By Route of Administration
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Herpes Labialis Drug Market Report by Segment

By Drug Type

• Acyclovir
• Valacyclovir
• Penciclovir
• Famciclovir
• Docosanol

By Route of Administration

• Oral
• Topical
• Combination

By Route of Administration

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Herpes Labialis Drugs Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa